Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089)
Dorothee G A Kasteleijn-Nolst Trenite, Bree D DiVentura, John R Pollard, Gregory L Krauss, Sarah Mizne, Jacqueline A French, Dorothee G A Kasteleijn-Nolst Trenite, Bree D DiVentura, John R Pollard, Gregory L Krauss, Sarah Mizne, Jacqueline A French
Abstract
Objective: To evaluate the effect of cenobamate in patients with photoparoxysmal-EEG response (PPR) to intermittent photic stimulation (IPS) as proof of principle of efficacy in patients with epilepsy.
Methods: In this multicenter, single-blind study, adults with photosensitive epilepsy, with/without concomitant antiepileptic drug therapy, underwent IPS under 3 eye conditions after a single dose of placebo (day -1, day 2) or cenobamate (day 1; 100, 250, or 400 mg). Complete suppression was a standardized photosensitivity range reduction to 0 over ≥1 time points for all eye conditions. Partial suppression was a ≥3-point reduction over ≥3 testing times vs the same time points on day -1 in ≥1 eye condition. Pharmacokinetics and safety were assessed.
Results: Of 6 evaluable patients, 5 reentered to receive higher doses. Cenobamate 100 mg produced partial suppression in 1 of 3 patients; 250 mg produced complete suppression in 1 of 4 and partial suppression in 4 of 4 patients; and 400 mg produced complete suppression in 1 of 4 and partial suppression in 2 of 4 patients. PPR was consistently reduced on days 1 and 2 (>24 hours after cenobamate) vs day -1 (placebo) with the 250- and 400-mg doses. Area under the plasma concentration-time curve (before dose to last measurable concentration) values between 201 and 400 μg/h/mL resulted in partial suppression in 4 of 6 (66%) patients. Most common adverse events were dizziness and somnolence.
Conclusions: This proof-of-principle study demonstrated that cenobamate is a potentially effective product for epilepsy.
Clinicaltrialsgov identifier: NCT00616148.
Classification of evidence: This study provides Class III evidence that, for patients with photosensitive epilepsy, cenobamate suppresses IPS-induced PPR.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures
References
- Binnie CD, Kasteleijn-Nolst Trenite DG, De Korte R. Photosensitivity as a model for acute antiepileptic drug studies. Electroencephalogr Clin Neurophysiol 1986;63:35–41.
- Di Prospero NA, Gambale JJ, Pandina G, et al. . Evaluation of JNJ-26489112 in patients with photosensitive epilepsy: a placebo-controlled, exploratory study. Epilepsy Res 2014;108:709–716.
- Kasteleijn-Nolst Trenite D, Genton P, Brandt C, Reed RC. The “photosensitivity model” is (also) a model for focal (partial) seizures. Epilepsy Res 2017;133:113–120.
- Lu Y, Waltz S, Stenzel K, Muhle H, Stephani U. Photosensitivity in epileptic syndromes of childhood and adolescence. Epileptic Disord 2008;10:136–143.
- Kasteleijn-Nolst Trenite DG, van Emde Boas W, Groenhout CM, Meinardi H. Preliminary assessment of the efficacy of Org 6370 in photosensitive epileptic patients: paradoxical enhancement of photosensitivity and provocation of myoclonic seizures. Epilepsia 1992;33:135–141.
- Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, Edelbroek PM, Oosting J. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs: evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996;25:225–230.
- Yuen ES, Sims JR. How predictive are photosensitive epilepsy models as proof of principle trials for epilepsy? Seizure 2014;23:490–493.
- Nakamura M, Shin H, Jang IS. Mechanism of action of cenobamate: preferential inhibition of the persistent sodium current. Neurology 2018;90(suppl 15):P5.278. Abstract.
- Younus I, Reddy DS. A resurging boom in new drugs for epilepsy and brain disorders. Expert Rev Clin Pharmacol 2018;11:27–45.
- Zaccara G, Schmidt D. Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development. Pharmacol Res 2016;104:38–48.
- Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Eleventh EILAT Conference (EILAT XI). Epilepsy Res 2013;103:2–30.
- Kasteleijn-Nolst Trenite D, Brandt C, Mayer T, et al. . Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: clear PK/PD relationship. Epilepsia 2015;56:924–932.
- French JA, Krauss GL, Kasteleijn D, DiVentura BD, Bagiella E. Effects of marketed antiepileptic drugs and placebo in the human photosensitivity screening protocol. Neurotherapeutics 2014;11:412–418.
- Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211–218.
- Scheffer IE, Berkovic S, Capovilla G, et al. . ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58:512–521.
- Kasteleijn-Nolst Trenite DG, Genton P, Parain D, et al. . Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007;69:1027–1034.
- Kasteleijn-Nolst Trenite DG, French JA, Hirsch E, et al. . Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled study. Epilepsy Res 2007;74:193–200.
- Vernillet L, Kamin M. Pharmacokinetics of cenobamate (YKP3089): results from single and multiple oral rising-dose studies in healthy subjects. Neurology 2018;90(suppl 15):P5.280. Abstract.
Source: PubMed